These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 36922331)

  • 1. Rifaximin Treatment for Individual and Multiple Symptoms of Irritable Bowel Syndrome With Diarrhea: An Analysis Using New End Points.
    Lacy BE; Chang L; Rao SSC; Heimanson Z; Sayuk GS
    Clin Ther; 2023 Mar; 45(3):198-209. PubMed ID: 36922331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome.
    Lembo A; Pimentel M; Rao SS; Schoenfeld P; Cash B; Weinstock LB; Paterson C; Bortey E; Forbes WP
    Gastroenterology; 2016 Dec; 151(6):1113-1121. PubMed ID: 27528177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea.
    Lembo A; Rao SSC; Heimanson Z; Pimentel M
    Clin Transl Gastroenterol; 2020 Mar; 11(3):e00144. PubMed ID: 32352714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rifaximin therapy for patients with irritable bowel syndrome without constipation.
    Pimentel M; Lembo A; Chey WD; Zakko S; Ringel Y; Yu J; Mareya SM; Shaw AL; Bortey E; Forbes WP;
    N Engl J Med; 2011 Jan; 364(1):22-32. PubMed ID: 21208106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-Blind Placebo-Controlled Study of Rifaximin and Lactulose Hydrogen Breath Test in Gulf War Veterans with Irritable Bowel Syndrome.
    Tuteja AK; Talley NJ; Stoddard GJ; Verne GN
    Dig Dis Sci; 2019 Mar; 64(3):838-845. PubMed ID: 30370492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial.
    Cash BD; Pimentel M; Rao SSC; Weinstock L; Chang L; Heimanson Z; Lembo A
    Therap Adv Gastroenterol; 2017 Sep; 10(9):689-699. PubMed ID: 28932270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating: Short- and Long-term Results From a Placebo-Controlled Randomized Trial.
    Holvoet T; Joossens M; Vázquez-Castellanos JF; Christiaens E; Heyerick L; Boelens J; Verhasselt B; van Vlierberghe H; De Vos M; Raes J; De Looze D
    Gastroenterology; 2021 Jan; 160(1):145-157.e8. PubMed ID: 32681922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
    Rivkin A; Rybalov S
    Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of purified clinoptilolite-tuff treatment in patients with irritable bowel syndrome with diarrhea: Randomized controlled trial.
    Anderle K; Wolzt M; Moser G; Keip B; Peter J; Meisslitzer C; Gouya G; Freissmuth M; Tschegg C
    World J Gastroenterol; 2022 Dec; 28(46):6573-6588. PubMed ID: 36569277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blinded randomised placebo controlled trial of enterosgel (polymethylsiloxane polyhydrate) for the treatment of IBS with diarrhoea (IBS-D).
    Howell CA; Kemppinen A; Allgar V; Dodd M; Knowles CH; McLaughlin J; Pandya P; Whorwell P; Markaryan E; Yiannakou Y
    Gut; 2022 Dec; 71(12):2430-2438. PubMed ID: 35760493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plecanatide Improves Abdominal Bloating and Bowel Symptoms of Irritable Bowel Syndrome with Constipation.
    Brenner DM; Sharma A; Rao SSC; Laitman AP; Heimanson Z; Allen C; Sayuk GS
    Dig Dis Sci; 2024 May; 69(5):1731-1738. PubMed ID: 38594429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomised, double-blind, placebo controlled multi-centre study to assess the efficacy, tolerability and safety of Enterosgel® in the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults.
    Kemppinen A; Howell C; Allgar V; Dodd M; Gregson J; Knowles C; McLaughlin J; Pandya P; Whorwell P; Markaryan E; Yiannakou Y
    Trials; 2020 Jan; 21(1):122. PubMed ID: 32000822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity.
    Pimentel M; Cash BD; Lembo A; Wolf RA; Israel RJ; Schoenfeld P
    Dig Dis Sci; 2017 Sep; 62(9):2455-2463. PubMed ID: 28589238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): study protocol for a randomised controlled trial.
    Leighton MP; Lam C; Mehta S; Spiller RC
    Trials; 2013 Jan; 14():10. PubMed ID: 23302220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
    Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS
    Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome.
    Fodor AA; Pimentel M; Chey WD; Lembo A; Golden PL; Israel RJ; Carroll IM
    Gut Microbes; 2019; 10(1):22-33. PubMed ID: 29708822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials.
    Brenner DM; Fogel R; Dorn SD; Krause R; Eng P; Kirshoff R; Nguyen A; Crozier RA; Magnus L; Griffin PH
    Am J Gastroenterol; 2018 May; 113(5):735-745. PubMed ID: 29545635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of vibegron for the treatment of irritable bowel syndrome in women: Results of a randomized, double-blind, placebo-controlled phase 2 trial.
    Lacy BE; King J; Shortino D; Schaumburg C; Haag-Molkenteller C; Chey WD
    Neurogastroenterol Motil; 2022 Dec; 34(12):e14448. PubMed ID: 35975404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?
    Cash BD; Lacy BE; Rao T; Earnest DL
    Expert Opin Pharmacother; 2016; 17(3):311-22. PubMed ID: 26559529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of the Combination of Pinaverium Bromide 100 mg Plus Simethicone 300 mg in Abdominal Pain and Bloating in Irritable Bowel Syndrome: A Randomized, Placebo-controlled Trial.
    Schmulson MJ; Chiu-Ugalde J; Sáez-Ríos A; López-Colombo A; Mateos-Pérez GJ; Remes-Troche JM; Sobrino-Cossio S; Soto-Pérez JC; Tamayo de la Cuesta JL; Teramoto-Matsubara OT; López-Alvarenga JC
    J Clin Gastroenterol; 2020 Apr; 54(4):e30-e39. PubMed ID: 31385885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.